Skip to main content
Evidence Snapshot

Class A carbapenemase KPC-2

CHEMBL5437 SINGLE PROTEIN Escherichia coli
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:19:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5437
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Class A carbapenemase KPC-2 as ChEMBL target CHEMBL5437, mapped to UniProt A8DS27. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Class A carbapenemase KPC-2
SINGLE PROTEIN · Escherichia coli
As of 2026-09-13
ChEMBL target ID
CHEMBL5437
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
A8DS27
beta-lactamase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Class A carbapenemase KPC-2 matters

As of 2026-09-13

Class A carbapenemase KPC-2 is reviewed as beta-lactamase (UniProt A8DS27); the current evidence base includes 2 approved drugs, 65 compounds, and 16 assays, with lead potency reaching pChEMBL 8.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 65 compounds, and 16 assays for this target. The dominant activity type is KI. CHEMBL4633785 is the current potency anchor at pChEMBL 8.7.

Use CHEMBL4633785 as the tractability anchor when discussing potency (pChEMBL 8.7).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 8.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Class A carbapenemase KPC-2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt A8DS27, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

65
Total Compounds
16
Total Assays
2
Approved Drugs
KI: 43.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4633785
 8.7 Ki —
No preferred name
CHEMBL1689063
 8.0 Ki Approved
No preferred name
CHEMBL4636953
 7.7 Ki —
No preferred name
CHEMBL3317857
 7.2 Ki Approved
No preferred name
CHEMBL4640702
 6.8 Ki —

Approved Drugs

Structure Compound First Approval
VABORBACTAM
CHEMBL3317857
 2017
AVIBACTAM
CHEMBL1689063
 2015
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:19:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5437